We here by submit Financial Results (Standalone and Consolidated) for the Quarter and Year ended 31.03.2026 along with Auditors Report thereon. Kindly take the same on your records.
AMBALALSA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Ambalal Sarabhai Enterprises reported strong FY2026 results with consolidated revenue of Rs 20,227L (up 3.1% YoY) and PAT of Rs 1,780L, a 261% jump from Rs 493L in FY2025. Standalone PAT grew 33% to Rs 1,099L from Rs 824L. The improvement was driven by reversal of provisions (Rs 520L), settlement gains, and improved operating performance in both Pharmaceuticals and Electronics segments. Exceptional items include Rs 460L litigation reversal (standalone) and Rs 82L labour code adjustment (consolidated). The Board approved intercorporate loans to three subsidiaries and reappointed key promoters including Executive Chairman and Managing Director.
The company delivered exceptional PAT growth in FY2026, driven largely by one-time gains and provisions reversals. Shareholders should note the loans to related parties and ongoing labour code adjustments that may impact future earnings.